Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Prostatic Neoplasms 3Neoplasm Metastasis 2Anatomic Stage IV Breast Cancer AJCC v8 2Oligo-metastatic Prostate Carcinoma 1Lymphoma, Follicular 1Dementia 1Cognitive Dysfunction 1Brain Neoplasms 1Anxiety Disorders 1Anomia 1Anatomic Stage I Breast Cancer AJCC v8 1Alzheimer Disease 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Hormones × Clear all
NCT06660862 2026-01-08

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

University of Chicago

Phase 4 Not yet recruiting
80 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03721341 2025-09-18

SABR-COMET 10

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 3 Active not recruiting
204 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡